Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Shares of Hims & Hers (HIMS) have jumped on Friday as the company is preparing to air its first Super Bowl ad promoting its compounded ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...

That disclaimer in mind, the AI indeed appears to have one significant blind spot in its news articles: the quality and accuracy ... unicorn Novo Nordisk's logo, complete with incomprehensible ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with ... and death among patients with end-stage kidney disease is "very high," particularly from cardiovascular ...

That disclaimer in mind, the AI indeed appears to have one significant blind spot in its news articles: the quality and accuracy of its citations ... version of the pharmaceutical unicorn Novo Nordisk ...